Branch Retinal Vein Occlusion (BRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.

Overview

The aim of this study is to evaluate the visual outcome and prognostic factors after intraocular injections of Bevacizumab or combination of Bevacizumab And Dexamethasone under pro re nata treatment regimen for Branch Retinal Vein Occlusion (BRVO) patients.

Full Title of Study: “Study on Branch Retinal Vein Occlusion Patients Receiving Bevacizumab and Dexamethasone or Bevacizumab Only on Naive Eyes.”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: March 2, 2021

Detailed Description

The aim of this study is to evaluate the clinical outcome after intraocular injections of Bevacizumab or combination of Bevacizumab and Dexamethasone under pro re nata treatment regimen for the patients with Branch Retinal Vein Occlusion (BRVO) patients. Mean change of logarithm of the minimal angle of resolution (logMAR) visual acuity (VA), central foveal thickness (CFT), contrast sensitivity (CS) as well as predictive factors including best-corrected visual acuity (BCVA), vision related questionnaires and various other ocular parameters will be assessed.

Interventions

  • Drug: Bevacizumab Ophthalmic and Intravitreal Dexamethasone
    • Pro re nata patients with BRVO will initially receive Bevacizumab and intravitreal Dexamethasone. And then depending on their clinical status of BRVO, Bevacizumab will be injected.
  • Drug: Bevacizumab Ophthalmic
    • Pro re nata patients with BRVO will receive Bevacizumab. And then depending on their clinical status of BRVO, Bevacizumab will be injected.

Arms, Groups and Cohorts

  • Experimental: BRVO: Bevacizumab and intravitreal Dexamethasone
    • Participants with BRVO will receive a combination of Bevacizumab and intravitreal Dexamethasone.
  • Active Comparator: BRVO: Bevacizumab
    • Participants with BRVO will receive Bevacizumab only.

Clinical Trial Outcome Measures

Primary Measures

  • Mean change in monocular BCVA in the treatment eye
    • Time Frame: Baseline, 1 week, 1month, 2 months, 3 months, and 6 months.
    • Monocular BCVA in the treatment eye is assessed by using ETDRS visual acuity charts at 4 meters is assessed and compared.
  • Mean change in binocular BCVA
    • Time Frame: Baseline, 1 week, 1month, 2 months, 3 months, and 6 months.
    • Binocular BCVA is assessed by using ETDRS visual acuity charts at 4 meters is assessed and compared.

Secondary Measures

  • Mean change in central subfield retinal thickness
    • Time Frame: Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.
    • Mean change in central subfield retinal thickness in the study eye, as determined by spectral domain optical coherence tomography (OCT) is assessed and compared.
  • Change in Humphrey 10-2 visual field in the treatment eye
    • Time Frame: Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.
    • Mean deviation (MD) of the Humphrey 10-2 visual field is assessed by a Humphrey 10-2 visual field test and compared.
  • Number of Bevacizumab. Treatments
    • Time Frame: Day 1 through Month 6
    • Number of injections provided to the patients during the 6 month period.
  • Mean change in NEI VFQ25
    • Time Frame: Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.
    • Scores from NEI VFQ25 questionnaire is assessed and compared.
  • Mean change in EQ-5D 5L
    • Time Frame: Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.
    • Scores from EQ-5D 5L questionnaire is assessed and compared.
  • Mean change in VisQoL scores
    • Time Frame: Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.
    • Scores from VisQoL questionnaire is assessed and compared.
  • Mean change in wavefront aberrations
    • Time Frame: Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.
    • Mean deviation (MD) of wavefront aberrations is assessed by Nidek OPD Scan III and compared.
  • Mean change in ocular surface and tear-film
    • Time Frame: Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.
    • Mean deviation (MD) of ocular surface and tear-film parameters is assessed by Oculus Keratographer test and compared.
  • Mean change in vessel density
    • Time Frame: Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.
    • Mean deviation (MD) of vessel density is assessed by Spectralis OCT2, Heidelberg-Engineering test and compared.
  • Side effects
    • Time Frame: Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.
    • Side effects are measured by a review of the participant’s medical and ophthalmic history.
  • People meeting driving standards
    • Time Frame: Baseline, 1 day, 1 week, 1month, 2 months, 3 months, and 6 months.
    • Percentage (%) of people meeting driving standards is assessed by an Esterman binocular visual field test and compared.

Participating in This Clinical Trial

Inclusion Criteria

1. Written informed consent must be obtained before any study assessment is performed 2. Diagnosis of visual impairment exclusively due to ME secondary to BRVO 3. BCVA score at Screening and Baseline between 10/40 (0.5) to 20/400 (0.05) on the Snellen chart. 4. Central foveal thickness (CFT) ≥ 300 µm 5. Naive Eyes Exclusion Criteria:

1. Pregnant or nursing (lactating) women 2. Stroke or myocardial infarction less than 3 months before Screening 3. Uncontrolled blood pressure defined as systolic value of >160 mm Hg or diastolic value of >100 mm Hg at Screening or Baseline. 4. Any active periocular or ocular infection or inflammation at Screening or Baseline in either eye 5. Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months before Baseline in either eye 6. Neovascularization of the iris or neovascular glaucoma in the study eye 7. Use of any systemic or ocular antivascular endothelial growth factor (anti-VEGF) drugs within 6 months before Baseline 8. Panretinal laser photocoagulation performed, anticipated or scheduled in the study eye 9. Focal or grid laser photocoagulation in the study eye 10. Use of intra- or periocular corticosteroids (including sub-Tenon) or ocular anti-VEGF treatment within 3 months before Screening in the study eye 11. Any use of intraocular corticosteroid implants (eg, dexamethasone [Ozurdex®], fluocinolone acetonide [Iluvien®]) in the study eye

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • He Eye Hospital
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Wei He, Study Chair, He Eye Specialist Hospital, Shenyang.
    • Jun Li, Principal Investigator, He Eye Specialist Hospital, Shenyang.
    • Emmanuel E Pazo, Study Director, He Eye Specialist Hospital, Shenyang.
  • Overall Contact(s)
    • Jun Li, M.D., Ph.D., 0086-15104083505, robin_lijun@sina.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.